Impact of Nintedanib and Anti-Angiogenic Agents on Uveal Melanoma Cell Behavior
Investigative Opthalmology & Visual Science · 2024-02-21 · 65 (2) · 30
DOI: 10.1167/iovs.65.2.30 ↗At a glance
Journal article in Investigative Opthalmology & Visual Science, published on 2024-02-21. Written by Vera E Pawlik and 5 co-authors. Institution: Department of Ophthalmology, University of Lübeck, Lübeck, Germany. Major MEDLINE topics: Vascular Endothelial Growth Factor A, Uveal Neoplasms, Indoles, Melanoma. Cited 3 times so far (Crossref); 155 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
The purpose of this study was to investigate the direct impact of the combined angiokinase inhibitor nintedanib as well as the anti-angiogenic agents ranibizumab, bevacizumab, and aflibercept on the primary uveal melanoma (UM) cell line Mel270 and liver metastasis UM cell line OMM2.5.
Methods
The metabolic activity, viability, and oxidative stress levels were analyzed by the Thiazolyl Blue Tetrazolium Bromide (MTT), LIVE/DEAD, and reactive oxygen species (ROS) assays. Expression of intracellular VEGF-A165 and VEGF receptor-2 was detected by immunofluorescent staining. The secretion of VEGF-A165 into the cell culture supernatants was evaluated by VEGF-A165 ELISA.
Results
Nintedanib, at a concentration of 1 µg/mL, resulted in a median reduction of metabolic activity (for Mel270 of approximately 38% and for OMM2.5 of 46% compared to the untreated control) without exerting toxicity in either cell line, whereas the other 3 substances did not result in any changes (which also means that none of the 4 substances led to an increased cell death). Moreover, nintedanib (1 µg/mL) induced oxidative stress in the Mel270 by approximately 1.2 to 1.5-fold compared to the untreated control, but not the OMM2.5 cells.
Conclusions
Nintedanib could suppress the growth of UM cells in a concentration-dependent manner. The metastatic UM cell line OMM2.5 was not sensitive to the pro-oxidant activity of nintedanib. This study was the first to investigate nintedanib in the context of UM. We propose further investigation of this substance to elucidate its effects on this tumor entity with the hope of identifying advantageous therapeutic options for future adjuvant tumor therapies.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Ophthalmology, University of Lübeck, Lübeck, Germany.
Cite
APA
Pawlik, V. E., Sonntag, S. R., Grisanti, S., Tura, A., Kakkassery, V., & Ranjbar, M. (2024). Impact of Nintedanib and Anti-Angiogenic Agents on Uveal Melanoma Cell Behavior. Investigative Opthalmology & Visual Science, 65(2), 30. https://doi.org/10.1167/iovs.65.2.30
Vancouver
Pawlik VE, Sonntag SR, Grisanti S, Tura A, Kakkassery V, Ranjbar M. Impact of Nintedanib and Anti-Angiogenic Agents on Uveal Melanoma Cell Behavior. Investigative Opthalmology & Visual Science. 2024;65(2):30. doi:10.1167/iovs.65.2.30
BibTeX
@article{Pawlik2024,
author = {Pawlik, Vera E and Sonntag, Svenja R and Grisanti, Salvatore and Tura, Aysegül and Kakkassery, Vinodh and Ranjbar, Mahdy},
title = {Impact of Nintedanib and Anti-Angiogenic Agents on Uveal Melanoma Cell Behavior},
journal = {Investigative Opthalmology & Visual Science},
year = {2024},
volume = {65},
number = {2},
pages = {30},
doi = {10.1167/iovs.65.2.30}
}
EUVIMED